Editas Medicine Names Meeta Chatterjee, Ph.D., to Board of Directors

December 17, 2020

CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it has appointed Meeta Chatterjee, Ph.D., to its Board of Directors.

Dr. Chatterjee is an accomplished biopharmaceutical executive with more than 30 years of broad strategic and operational experience in research and development, mergers and acquisition evaluation, in-licensing, and externalization activities. She currently serves as Senior Vice President of Global Business Development at Legend Biotech where she provides oversight for all business development activities including prioritizing opportunities, managing evaluations, and executing transactions. She also leads Alliance Management activities at Legend. Prior to joining Legend, Dr. Chatterjee was Head of Strategy, Transactions, and Operations in the Business Development and Licensing (BD&L) group at Merck Research Labs. In that role, Dr. Chatterjee oversaw all discovery and late-stage transactions worldwide and early-stage transactions in key geographies. She was also responsible for Merck Research Labs BD&L governance as well as out-licensing efforts.

“I am very pleased to welcome Meeta to our Board of Directors. She is an accomplished biopharmaceutical executive with extensive strategic and operational experience and achievements in business development activities. Her work has led to several business transactions and collaborations that brought important, new medicines to patients,” said James C. Mullen, Chairman of the Board of Directors, Editas Medicine.

“I am thrilled to join Editas Medicine’s Board of Directors at this exciting time when the company is bringing important programs to the clinic. I look forward to being part of this exceptional team and applying my experience to help advance Editas’ innovative CRISPR technology to develop impactful medicines for people living with serious diseases of unmet medical need,” said Dr. Chatterjee.

Dr. Chatterjee holds a B.A. in Physics from St. Xavier’s University in Ahmedabad, India, and Rutgers University, and a Ph.D. in Physiology from Rutgers University. She completed her post-doctoral fellowship in the Department of Physiology at the University of Virginia School of Medicine.

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "target," "should," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.

Contacts:
Media
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com

Investors
Editas Medicine Investor Relations
(617) 401-9052
ir@editasmed.com

Source: Editas Medicine, Inc.